DAY ONE - 12 NOVEMBER

Investment Forum Programme

Oxford Global's ½ Day Investment Forum will connect scientifically credible early-stage biotech companies with Seed, Series A and Series B investors focused on advanced therapies, cell and gene therapy, regenerative medicine, and enabling technologies.

The forum will combine investor-led discussion, curated company exposure, structured networking and a pitch-style feedback session, creating a targeted environment for meaningful investor–company engagement.

DATE

Thursday 12 November 2026

TIME

14:25 - 17:40 GMT

VENUE

Novotel London West

Investment Programme

14:25 – 14:55

Investor-Focused Panel Discussion

Building Investor Confidence And Translating Science Into Value

This opening panel will explore what investors are currently looking for in advanced therapies and how early-stage companies can become investor-ready.

Key topics:

  • What do investors look for in advanced therapies such as cell and gene therapy and regenerative medicine, and across key areas like oncology, rare disease, and autoimmune disease?
  • What does it take for biotech companies to become truly investor-ready in this space?
  • Where is capital flowing next in advanced therapies, and what is driving those investment decisions?

Moderator: Ilya Yasny, Partner, Lancebio Ventures

Panellists:

Oliver Hemmings, Analyst, Delin Ventures

Sven Kili, Partner, Saisai Ventures

Cell 2026 Investment Forum Panellists Supporting Image

14:55 - 15:40

Panel Discussion

Investing In ATMP Platforms And Enabling Technologies

This session will focus on the platforms and technologies attracting investor attention beyond individual therapeutic assets.

Key topics:


1. Introductions and Investment Priorities 
- Each panellist briefly introduces their organisation, investment stage and current ATMP investment priorities
2. Investing in Therapeutic Platforms vs Enabling Technologies 
- What makes a technology platform investable: a clear therapeutic pipeline or the ability to serve multiple therapeutic developers?
- How do investors assess commercial scalability, differentiation and value creation?
3. Manufacturing Innovation, Viral Vectors and iPSC Platforms 
- Which manufacturing innovations, including viral vectors and iPSC platforms, offer the greatest potential to reduce costs and improve scalability?
- What evidence of technical validation, customer demand and commercial readiness do investors expect?
4. Next-Generation Platforms: Delivery Technologies, Gene Editing and AI 
- Which emerging delivery technologies, gene editing approaches and AI-enabled platforms offer the greatest therapeutic potential?
- What differentiates an exciting scientific technology from an investable platform capable of generating a therapeutic pipeline?
5. Investment Outlook: Where Will Capital Flow Next? 
- Which ATMP platforms and enabling technologies are likely to attract the greatest investment over the next three to five years?
- What is the single most important factor early-stage companies must demonstrate to secure investment?

Moderator: Carolyn Porter, Chief Business Officer, Cell & Gene Therapy Catapult 

Panellists:

Konstantinos Gkatzis, Principal, Solyco Capital UK & Europe
Stephanie Mattsson, Director Venture Development, CCRM Nordic
Stefano Lomartire, Investment Manager, Apposite Capital 
Sarah Domoney, Venture Analyst, Saisei Ventures
Simon Brunner, Principal, Flagship Pioneering

Cell 2026 Investment Forum Panellists Supporting Image 2-1

15:40 – 16:40

Investor & Company Afternoon Tea Networking Break

A dedicated networking period for investors to meet prequalified companies, supported by curated introductions. 


15:40 – 16:40

Curated 1-2-1 Meetings / Investor Office Hours

Structured meetings will be arranged between investors and selected companies based on funding stage, modality, technology focus and fundraising requirements.

Investee companies will be prequalified based on:

  • Scientific credibility
  • Relevance to advanced therapies, CGT or enabling technologies
  • Seed, Series A or Series B funding stage
  • Active or near-term fundraising plans
  • Clear development milestones
  • Strong management or scientific leadership
  • Investor-ready materials
1to1 Photo

16:40 - 17:20

Founders Ask Investors: Open Q&A

An interactive, boardroom-style session bringing together biotech founders and investors for an open, practical discussion. Founders will have the opportunity to ask questions directly about fundraising, investor engagement, due diligence, deal structures and building successful investor relationships.

All participating investors are invited to contribute their perspectives, offering practical advice and insights from their investment experience.


17:20 - 17:40

Closing Forum Analyst Presentation

What Investors Actually Want in Advanced Therapies: Analyst Perspectives

The forum will close with a concise investor/analyst-led overview of current investment sentiment in advanced therapies.

Key topics:

  • How investors are making yes/no decisions
  • Why CGT sentiment is challenging and how companies can respond
  • What separates fundable from unfundable science
  • Which technologies and business models are attracting capital

David Porter, Founding Partner, Apposite Capital 

Cell 2026 Investment Forum David Porter

17:40

Networking Drinks & Canapé Reception

Forum participants will continue discussions during the wider Cell 2026 networking reception.

Secure Your Place at the Investment Forum

Join an exclusive community of investors, senior decision-makers and industry leaders for high-value conversations, strategic connections and new opportunities.

Register today by selecting the Investor Pass or Investee Pass and put yourself at the heart of the conversations shaping the future of investment.